A DNMT1-specific inhibitor, GSK3685032, was recently used to induce gene activation and hypomethylation in AML cell lines and was effective in human AML xenograft models (Pappalardi et al. 2021). This evidence concerns the gene DNMT1 and acute myeloid leukemia.